• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对氧化应激和NRF2激活的镰状细胞病药物发现创新——简短综述

Innovations in Drug Discovery for Sickle Cell Disease Targeting Oxidative Stress and NRF2 Activation-A Short Review.

作者信息

Starlard-Davenport Athena, Palani Chithra D, Zhu Xingguo, Pace Betty S

机构信息

Department of Genetics, Genomics and Informatics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38103, USA.

Department of Pediatrics, Division of Hematology/Oncology, Augusta University, Augusta, GA 30912, USA.

出版信息

Int J Mol Sci. 2025 Apr 28;26(9):4192. doi: 10.3390/ijms26094192.

DOI:10.3390/ijms26094192
PMID:40362428
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12071363/
Abstract

Sickle cell disease (SCD) is a monogenic blood disorder characterized by abnormal hemoglobin S production, which polymerizes under hypoxia conditions to produce chronic red blood cell hemolysis, widespread organ damage, and vasculopathy. As a result of vaso-occlusion and ischemia-reperfusion injury, individuals with SCD have recurrent pain episodes, infection, pulmonary disease, and fall victim to early death. Oxidative stress due to chronic hemolysis and the release of hemoglobin and free heme is a key driver of the clinical manifestations of SCD. The net result is the generation of reactive oxygen species that consume nitric oxide and overwhelm the antioxidant system due to a reduction in enzymes such as superoxide dismutase and glutathione peroxidase. The primary mechanism for handling cellular oxidative stress is the activation of antioxidant proteins by the transcription factor NRF2, a promising target for treatment development, given the significant role of oxidative stress in the clinical severity of SCD. In this review, we discuss the role of oxidative stress in health and the clinical complications of SCD, and the potential of NRF2 as a treatment target, offering hope for developing effective therapies for SCD. This task requires our collective dedication and focus.

摘要

镰状细胞病(SCD)是一种单基因血液疾病,其特征是产生异常的血红蛋白S,该蛋白在缺氧条件下会聚合,导致慢性红细胞溶血、广泛的器官损伤和血管病变。由于血管阻塞和缺血再灌注损伤,SCD患者会反复出现疼痛发作、感染、肺部疾病,并过早死亡。慢性溶血以及血红蛋白和游离血红素的释放所导致的氧化应激是SCD临床表现的关键驱动因素。最终结果是产生活性氧物种,这些活性氧会消耗一氧化氮,并由于超氧化物歧化酶和谷胱甘肽过氧化物酶等酶的减少而使抗氧化系统不堪重负。处理细胞氧化应激的主要机制是转录因子NRF2对抗氧化蛋白的激活,鉴于氧化应激在SCD临床严重程度中的重要作用,NRF2是一个很有前景的治疗开发靶点。在这篇综述中,我们讨论了氧化应激在健康和SCD临床并发症中的作用,以及NRF2作为治疗靶点的潜力,为开发有效的SCD治疗方法带来了希望。这项任务需要我们共同的奉献和专注。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dad/12071363/1842eceb4a6a/ijms-26-04192-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dad/12071363/f8f801408726/ijms-26-04192-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dad/12071363/1842eceb4a6a/ijms-26-04192-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dad/12071363/f8f801408726/ijms-26-04192-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dad/12071363/1842eceb4a6a/ijms-26-04192-g002.jpg

相似文献

1
Innovations in Drug Discovery for Sickle Cell Disease Targeting Oxidative Stress and NRF2 Activation-A Short Review.针对氧化应激和NRF2激活的镰状细胞病药物发现创新——简短综述
Int J Mol Sci. 2025 Apr 28;26(9):4192. doi: 10.3390/ijms26094192.
2
Impacts of oxidative stress and anti-oxidants on the development, pathogenesis, and therapy of sickle cell disease: A comprehensive review.氧化应激和抗氧化剂对镰状细胞病的发展、发病机制和治疗的影响:全面综述。
Biomed Pharmacother. 2024 Jul;176:116849. doi: 10.1016/j.biopha.2024.116849. Epub 2024 Jun 1.
3
The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease.镰状细胞病中的红细胞-炎症恶性循环。
Front Immunol. 2020 Mar 13;11:454. doi: 10.3389/fimmu.2020.00454. eCollection 2020.
4
Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate.使用Nrf2激活剂富马酸二甲酯控制镰状细胞病中的氧化应激和炎症
Antioxid Redox Signal. 2017 May 10;26(14):748-762. doi: 10.1089/ars.2015.6571. Epub 2016 Mar 30.
5
Mechanisms of NRF2 activation to mediate fetal hemoglobin induction and protection against oxidative stress in sickle cell disease.NRF2 激活机制介导胎儿血红蛋白诱导和镰状细胞病氧化应激保护。
Exp Biol Med (Maywood). 2019 Feb;244(2):171-182. doi: 10.1177/1535370219825859. Epub 2019 Jan 23.
6
Triterpenoid inducers of Nrf2 signaling as potential therapeutic agents in sickle cell disease: a review.作为镰状细胞病潜在治疗药物的Nrf2信号通路三萜类诱导剂:综述
Front Med. 2015 Mar;9(1):46-56. doi: 10.1007/s11684-015-0375-1. Epub 2014 Dec 15.
7
Role of oxidative stress in the pathogenesis of sickle cell disease.氧化应激在镰状细胞病发病机制中的作用。
IUBMB Life. 2012 Jan;64(1):72-80. doi: 10.1002/iub.584. Epub 2011 Nov 30.
8
Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation.通过激活Nrf2改善镰状细胞模型小鼠的炎症和组织损伤。
Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):12169-74. doi: 10.1073/pnas.1509158112. Epub 2015 Sep 14.
9
Targeting NADPH oxidase decreases oxidative stress in the transgenic sickle cell mouse penis.靶向 NADPH 氧化酶可降低转基因镰状细胞小鼠阴茎中的氧化应激。
J Sex Med. 2012 Aug;9(8):1980-7. doi: 10.1111/j.1743-6109.2012.02798.x. Epub 2012 May 23.
10
Sickle cell disease: role of reactive oxygen and nitrogen metabolites.镰状细胞病:活性氧和氮代谢产物的作用
Clin Exp Pharmacol Physiol. 2007 Sep;34(9):926-32. doi: 10.1111/j.1440-1681.2007.04639.x.

引用本文的文献

1
Hypoxia, Inflammation, and Cytokine Crosstalk in Sickle Cell Disease: From Mechanisms to Modulation- A Narrative Review.镰状细胞病中的缺氧、炎症和细胞因子相互作用:从机制到调节——一篇叙述性综述
Pediatric Health Med Ther. 2025 Aug 27;16:217-225. doi: 10.2147/PHMT.S544217. eCollection 2025.
2
The Interplay Between Oxidant/Antioxidant System, Transcription Factors, and Non-Coding RNA in Lung Cancer.肺癌中氧化还原系统、转录因子与非编码RNA之间的相互作用
Int J Mol Sci. 2025 Aug 8;26(16):7679. doi: 10.3390/ijms26167679.

本文引用的文献

1
Targeting sickle cell pathobiology and pain with novel transdermal curcumin.用新型透皮姜黄素靶向镰状细胞病理生物学和疼痛。
PNAS Nexus. 2025 Feb 13;4(2):pgaf053. doi: 10.1093/pnasnexus/pgaf053. eCollection 2025 Feb.
2
MiR-142-5p mediated Nrf2 dysregulation in gestational diabetes mellitus and its impact on placental angiogenesis.MiR-142-5p介导妊娠期糖尿病中Nrf2失调及其对胎盘血管生成的影响。
Placenta. 2024 Dec;158:192-199. doi: 10.1016/j.placenta.2024.10.021. Epub 2024 Oct 24.
3
Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.
Lovotibeglogene Autotemcel(Lovo-Cel)基因疗法治疗美国镰状细胞病和复发性血管阻塞性事件患者的成本效益分析。
Pharmacoeconomics. 2024 Jun;42(6):693-714. doi: 10.1007/s40273-024-01385-9. Epub 2024 Apr 29.
4
Exagamglogene Autotemcel for Severe Sickle Cell Disease.依洛尤单抗治疗严重镰状细胞病。
N Engl J Med. 2024 May 9;390(18):1649-1662. doi: 10.1056/NEJMoa2309676. Epub 2024 Apr 24.
5
Simvastatin-Mediated Nrf2 Activation Induces Fetal Hemoglobin and Antioxidant Enzyme Expression to Ameliorate the Phenotype of Sickle Cell Disease.辛伐他汀介导的Nrf2激活诱导胎儿血红蛋白和抗氧化酶表达以改善镰状细胞病的表型。
Antioxidants (Basel). 2024 Mar 11;13(3):337. doi: 10.3390/antiox13030337.
6
Reactive Oxygen Species Signaling and Oxidative Stress: Transcriptional Regulation and Evolution.活性氧信号传导与氧化应激:转录调控与进化
Antioxidants (Basel). 2024 Mar 1;13(3):312. doi: 10.3390/antiox13030312.
7
Therapeutic potentials of catalase: Mechanisms, applications, and future perspectives.过氧化氢酶的治疗潜力:作用机制、应用及未来展望。
Int J Health Sci (Qassim). 2024 Mar-Apr;18(2):1-6.
8
CASGEVY Makes History as FDA Approves First CRISPR/Cas9 Genome Edited Therapy.随着美国食品药品监督管理局(FDA)批准首个CRISPR/Cas9基因编辑疗法,CASGEVY创造了历史。
Hum Gene Ther. 2024 Jan;35(1-2):1-4. doi: 10.1089/hum.2023.29263.bfs.
9
Bach1 inhibitor HPP-D mediates γ-globin gene activation in sickle erythroid progenitors.Bach1 抑制剂 HPP-D 可介导镰状红细胞祖细胞中 γ-珠蛋白基因的激活。
Blood Cells Mol Dis. 2024 Jan;104:102792. doi: 10.1016/j.bcmd.2023.102792. Epub 2023 Aug 17.
10
Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial.用精氨酸治疗镰状细胞病(STArT):一项 3 期随机对照试验的研究方案。
Trials. 2023 Aug 17;24(1):538. doi: 10.1186/s13063-023-07538-z.